(142 days)
Not Found
No
The summary describes a bone cement and does not mention any AI or ML components or functionalities.
Yes
The device is a bone cement used for the fixation of pathological fractures of the vertebral body, which is a treatment for a medical condition.
No
The device is a bone cement used for the fixation of pathological fractures and for pain relief through vertebroplasty or kyphoplasty procedures. It is a treatment device, not one that gathers information to identify or diagnose a condition.
No
The device description clearly states it is a Polymethyl Methacrylate cement, which is a physical material, not software.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to examine specimens taken from the human body (like blood, urine, tissue) to provide information about a person's health. This information is used for diagnosis, monitoring, or screening.
- Device Description: The description clearly states that Vertaplex HV Radiopaque Bone Cement is a Polymethyl Methacrylate cement injected directly into the fractured vertebral body. This is a material used within the body for structural support and fixation.
- Intended Use: The intended use is for the fixation of pathological fractures of the vertebral body using vertebroplasty or kyphoplasty procedures. This is a surgical procedure performed on the patient's body, not an analysis of a specimen taken from the body.
Therefore, based on the provided information, Vertaplex HV Radiopaque Bone Cement is a surgical implant/material used in a medical procedure, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
Vertaplex HV Radiopaque Bone Cement is indicated for the fixation of pathological fractures of the vertebral body using vertebroplasty or kyphoplasty procedures. Painful vertebral compression fractures may result from osteoporosis, benign lesions (hemangioma), and malignant lesions (metastatic cancers, myeloma).
Product codes (comma separated list FDA assigned to the subject device)
NDN, LOD
Device Description
Vertaplex HV is Polymethyl Methacrylate cement used for the treatment of painful vertebral fractures based on the predicate device Stryker Vertaplex PMMA Radiopaque Bone Cement (Vertaplex). Vertaplex HV can be injected directly into the fractured vertebral body by either Vertebroplasty or Kyphoplasty procedures to relieve pain.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Vertebral body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Testing shows that the device meets similar performance specifications as those for the predicate device. No new types of issues of safety or effectiveness are introduced by using this device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3027 Polymethylmethacrylate (PMMA) bone cement.
(a)
Identification. Polymethylmethacrylate (PMMA) bone cement is a device intended to be implanted that is made from methylmethacrylate, polymethylmethacrylate, esters of methacrylic acid, or copolymers containing polymethylmethacrylate and polystyrene. The device is intended for use in arthroplastic procedures of the hip, knee, and other joints for the fixation of polymer or metallic prosthetic implants to living bone.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Polymethylmethacrylate (PMMA) Bone Cement.”
0
Image /page/0/Picture/0 description: The image shows a handwritten sequence of characters, seemingly a code or identifier. The sequence reads 'K09/606', with a forward slash separating the '09' from '606'. The handwriting is somewhat stylized, with rounded forms for the zeros and sixes.
4100 E. Milham Avenue
Kalamazoo, MI 49001
t: 269 323 7700 f: 269 324 5412 www.stryker.com
OCT 2 3 2009
stryker
Instruments
510(k) Summary
| 510(k) Owner: | Stryker Instruments
4100 E. Milham Avenue
Kalamazoo, MI 49001
(p) 269-323-7700
(f) 269-324-5412 |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Becky E. Ditty
Regulatory Affairs Analyst |
| Registration No .: | 1811755 |
| Trade Name: | Stryker Vertaplex HV |
| Common Name: | PMMA Bone Cement |
| Classification Name: | Polymethylmethacrylate (PMMA) Bone Cement |
| Regulation Number: | $888.3027 |
| Predicate Device: | Stryker Vertaplex Radiopaque Bone Cement (K072118) |
| Device Description: | Vertaplex HV is Polymethyl Methacrylate cement used for the treatment of
painful vertebral fractures based on the predicate device Stryker Vertaplex
PMMA Radiopaque Bone Cement (Vertaplex). Vertaplex HV can be injected
directly into the fractured vertebral body by either Vertebroplasty or Kyphoplasty
procedures to relieve pain. |
| Indications for Use: | Vertaplex HV Radiopaque Bone Cement is indicated for the fixation of
pathological fractures of the vertebral body using vertebroplasty or kyphoplasty
procedures.
Painful vertebral compression fractures may result
from
osteoporosis, benign lesions (hemangioma), and malignant lesions (metastatic
cancers, myeloma). |
| Substantial Equivalence
(SE) Rational: | Stryker Vertaplex HV is composed of the same chemical components as Stryker
Vertaplex PPMA Bone Cement and is equivalent in performance. |
| Safety and Effectiveness: | Stryker Vertaplex HV is substantially equivalent in design, materials, intended
use and performance to the predicate device, Stryker Vertaplex PMMA Bone
Cement (K072118). Testing shows that the device meets similar performance
specifications as those for the predicate device. No new types of issues of
safety or effectiveness are introduced by using this device. |
| Submitted by: | Becky E. Ditty
Regulatory Affairs Analyst
Signature |
| Date Submitted: | June 1, 2009 |
1
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three abstract, wave-like shapes stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002
Stryker Instruments % Ms. Becky E. Ditty Regulatory Affairs Analyst 4100 E. Milham Avenue Kalamazoo, MI 49001
OCT 2 3 2009
Re: K091606
Trade/Device Name: Vertaplex HV Regulation Number: 21 CFR 888.3027 Regulation Name: Polymethylmethacrylate (PMMA) bone cement Regulatory Class: II Product Code: NDN, LOD Dated: October 6, 2009 Received: October 9, 2009
Dear Ms. Ditty:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
2
Page 2 - Ms. Becky E. Ditty
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm111800 html for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Allo, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 (1)53) Pred. 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll the (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Mark M. Milkusson
Mark N. Melkerson Director Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(K) Number (if known): ____________________________________________________________________________________________________________________________________________________
Device Name: Vertaplex HV ____________________________________________________________________________________________________________________________________________________
Indications for Use
Vertaplex HV Radiopaque Bone Cement is indicated for the fixation of pathological fractures of the vertebral body using vertebroplasty or kyphoplasty procedures. Painful vertebral compression fractures may result from osteoporosis, benign lesions (hemangioma), and malignant lesions (metastatic cancers, myeloma).
Prescription Use _ X (Part 21 CFR 801 Subpart D)
and/or
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
FOR M. MELKERSON
(Bivision Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K091606